Table 4.

Adverse event summary by severity and relationship to study drug

	DMQ (n = 58)			Placebo (n = 57)
Adverse event characteristic	# of Events	# of Subjects	% of Subjects	# of Events	# of Subjects	% of Subjects
Severity
No AEs reported	0	32	55%	0	32	56%
Mild	52	15	26%	32	10	18%
Moderate	17	9	16%	16	12	21%
Severe	2	2	3%	3	3	5%
Relationship to Study Drug
No AEs reported	0	32	55%	0	32	56%
Not related	18	5	9%	30	13	23%
Unlikely related	28	12	21%	14	8	14%
Possibly related	15	6	10%	7	4	7%
Probably related	10	3	5%	0	0	0%

The number and severity of all adverse events (AEs) occurring during placebo and Nuedexta (DMQ) intervals of the trial are listed, along with their likelihood of being related to study treatment. Counts and percentages of patients summarize the most severe or most closely related event reported for each patient during a given treatment interval